Get the content you want anytime you want.

A New Approach to Understanding Multidrug-resistant Infections


Vikas Gupta, PharmD, BCPS, director of Clinical Strategy at Becton Dickinson, explains his team’s unique approach to understanding multidrug-resistant infections.
Interview Transcript (slightly modified for readability)
“[When looking at multidrug-resistant organisms], it’s not just [about] how much, but where. What we wanted to do is characterize [it], in different types of settings. A lot of the focus has been around hospital-acquired infections or healthcare-associated infections, and how much is in that. And, in fact, [the] Antibiotic Threat Report from the [Centers for Disease Control and Prevention] focused a lot on that antibiotic threat in healthcare-associated infections. [It’s] a very important report, [which has] very much heightened the awareness of these resistance pathogens.
But we wanted to focus on [the topic] in a different [way that would] complement their report, [by looking] at different settings; [so, not just] patients that come to the hospital or develop these [infections] in the hospital, but also in the nonacute-care setting. Many of the clinicians and the companies that we spoke with that approached us with these types of questions felt that there was a higher prevalence [of multidrug-resistant organisms] out there and that, potentially, even in the nonacute-care setting, there may be more prevalence of these resistant organisms; this is one of the reasons why we looked at this from a different angle overall.”
To stay informed on the latest in infectious disease news and developments, please sign up for our weekly newsletter.

The new test can differentiate between Lyme disease and 7 other tick-borne diseases.